EWTX250117P22500
- 0.30
- 0.000.00%
Edgewise Therapeutics Newsroom
Evercore ISI Group Maintains Outperform on Edgewise Therapeutics, Raises Price Target to $50
Edgewise Therapeutics Analyst Ratings
Evercore Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Maintains Target Price $50
Truist Financial Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Maintains Target Price $50
A Quick Look at Today's Ratings for Edgewise Therapeutics(EWTX.US), With a Forecast Between $50 to $50
Truist Financial Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Maintains Target Price $50
RBC Capital Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Raises Target Price to $44
Edgewise Therapeutics Analyst Ratings
Truist Financial Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating
Edgewise Therapeutics Initiated at Outperform by Evercore ISI Group
Evercore Initiates Edgewise Therapeutics(EWTX.US) With Buy Rating, Announces Target Price $45
Edgewise Therapeutics Is Maintained at Outperform by Wedbush
Edgewise Therapeutics Analyst Ratings
RBC Capital Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Maintains Target Price $42
Piper Sandler Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Maintains Target Price $51
Truist Financial Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating
Piper Sandler Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Raises Target Price to $51
Edgewise Therapeutics Analyst Ratings
Piper Sandler Reaffirms Their Buy Rating on Edgewise Therapeutics (EWTX)
Analysts Offer Insights on Healthcare Companies: Edgewise Therapeutics (EWTX) and AnaptysBio (ANAB)